查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1146376

低氧疗法市场 - COVID-19 的增长、趋势、影响和预测 (2022-2027)

Hypoxia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 90 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，缺氧疗法市场预计将以 3.5% 的复合年增长率增长。

2019 年冠状病毒病 (COVID-19) 会导致严重的低氧血症，加剧 COVID-19 的损害。此外，缺氧对 COVID-19 患者的确切影响尚不清楚。在 COVID-19 感染早期，一些 COVID-19 患者会出现一种称为“无声缺氧”的情况，据观察，缺氧会加剧感染并加剧肺细胞破坏。 Coronavirus Disease-2019 中的无声缺氧：它更危险吗？”研究发现，缺氧会破坏 Coronavirus disease-2019 患者的肺细胞。一项回顾性队列研究”，2022 年 6 月发表于 Lung India，表明大约 32% 至 65% 的 COVID-19 患者出现无症状缺氧。此外，根据 2020 年 5 月发表在《欧洲医学与药学评论》上的一项题为“治疗 COVID-19 患者缺氧的氧疗策略和技术”的研究，早期氧疗可有效治疗 COVID-19 患者的缺氧因此，市场增长预计将受到 COVID-19患者对氧疗需求增加的影响。

市场受到製药行业研发活动增加和缺氧流行率上升的推动。根据这项研究，“在低收入和中等收入国家就诊于医疗机构的儿科和成人患者中低氧血症的患病率：系统评价和荟萃分析的方案”发表于 2020 年 3 月的系统评价，12 岁儿童低氧血症的患病率：因此，缺氧患病率的增加预计会增加对疾病管理中治疗选择的需求，并推动市场增长。

此外，预计研发活动的增加将支持预测期内的市场扩张。根据 2021 年 2 月发表在 Critical Care 上的一项题为“头盔 CPAP 治疗 ICU 外缺氧性肺炎：一项观察性研究”的研究，有有效的界面据说是头盔。头盔式 CPAP 可作为一种挽救生命的治疗方法，提高患者的生存率。此外，增加研发支出预计将推动市场增长。根据美国研究与製药製造商协会 (PhRMA) 2020 年 9 月的更新，PhRMA 成员公司在 2020 年的研发活动中投资了约 830 亿美元。此外，根据同一消息来源 PhRMA，2020 年，生物製药公司正在研发 260 多种针对各种疾病（包括 COVID-19）的疫苗。

因此，上述所有因素，例如缺氧患病率上升和研发活动增加，预计都将推动市场增长。然而，严格的政府法规和替代品的可用性可能会限制预测期内的市场增长。

主要市场趋势

预测期内哮喘病有望健康增长

哮喘是世界上最普遍的疾病之一，可能是一种致命的疾病，会损害人的正常呼吸能力。哮喘是一种慢性疾病，它会收缩和拉伸肺部的气道，导致反復出现气短、支气管痉挛和可逆性气流阻塞。烟草使用也显着增加，这加剧了哮喘症状。此外，随着工业化进程的推进，哮喘患者的数量也在不断增加，未来对哮喘药物的需求可能会增加。哮喘患者数量的增加预计将推动这一领域的增长。哮喘患病率和发病率的显着增加导致患者数量增加，从而导致对这些药物的需求增加。根据世界卫生组织 (WHO) 2021 年情况说明书，哮喘是一种主要的非传染性疾病 (NCD)，影响儿童和成人。在全球范围内，估计 2.62 亿人将被感染，2020 年将有 461,000 人死亡。

此外，市场参与者增加的研发活动和产品发布被认为正在推动市场的增长。例如，2021年3月，GlaxoSmithKline PC将与IQVIA Pty Ltd合作开展第三项研究，以评估GSK3511294（Depemokimab）在患有严重未控制哮喘的成人和青少年中的疗效和安全性，III期临床试验已经启动。该研究计划于 2023 年 10 月完成。同样，2021 年 2 月，AstraZeneca PLC 将与Amgen Inc.合作开展第二项研究，以评估 5 至 11 岁以下哮喘儿童单次皮下注射（SC）剂量的 tezeperumab 的药代动力学（PK）概况。 I期临床试验已经开始。该考试计划于 2021 年 9 月结束。因此，上述因素预计将在预测期内推动分部增长。

因此，所有上述因素，例如哮喘患者缺氧患病率上升，预计将在预测期内推动市场增长。

预计在预测期内北美将占据重要的市场份额

由于缺氧症的普遍存在、研发支出的增加以及个人可支配收入的增加，北美在全球缺氧症市场占据主导地位。缺氧主要与哮喘、慢性阻塞性肺病和肺炎等呼吸系统疾病有关，而慢性阻塞性肺病和哮喘等疾病发病率的增加正在推动市场的扩大。例如，根据国家心肺血液研究所 2022 年 3 月的更新，美国每年有超过 1500 万人患有慢性阻塞性肺病。慢性阻塞性肺病是美国第四大死因，是一个主要的绊脚石。

此外，根据 2021 年加拿大哮喘年度报告，估计每天有 317 名加拿大人被诊断出患有哮喘。每年有超过 70,000 人因哮喘发作而住院。哮喘是加拿大第三大常见慢性病，每年影响超过 380 万加拿大人。哮喘和慢性阻塞性肺病的高患病率增加了对治疗这些疾病的药物的需求，推动了该地区的增长。

此外，各种机构不断增加的研究和开发活动可能会推动市场的增长，预计将呈现高增长。例如，2022 年 8 月，Pgharmazz Inc（美国）获得中央药品监督管理局的研究药物申请批准，在缺氧缺血条件下开展 Sovateltide 的二期临床试验。此外，2022 年 1 月，第一款用于医疗级连续氧气监测的非侵入式可穿戴设备 OxiWear 筹集了 125 万美元的资金。

因此，上述所有因素都有望在预测期内提振市场。

竞争格局

由于存在一些大型参与者，该市场是一个整合市场。随着技术进步和产品创新不断，中小型公司正在通过以具有竞争力的价格将新设备推向市场来增加其市场占有率。市场参与者包括 Thermo Fisher Scientific Inc.、Resmed、Hamilton Medical、Merck KGaA、Spotlight Labs, LLC.、HypOxygen、PharmaShots 和 Hancock Medical Inc。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 缺氧的发生率增加
    • 激活研发
  • 市场製约因素
    • 存在严格的政府法规和替代产品
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按类型
    • 缺氧缺氧
    • 贫血缺氧
    • 停滞缺氧
    • 细胞毒性缺氧
  • 按疾病分类
    • 慢性阻塞性肺疾病 (COPD)
    • 肺炎
    • 支气管哮喘
    • 其他
  • 最终用户
    • 医院/诊所
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美洲

第六章竞争格局

  • 公司简介
    • Thermo Fisher Scientific Inc.
    • Resmed
    • Merck KGaA
    • Spotlight Labs, LLC.
    • HypOxygen
    • Hancock Medical Inc.
    • Fisher & Paykel Healthcare Limited
    • Invacare Corporation
    • Natus Medical Incorporated
    • Getinge AB
    • Hamilton Company
    • Koninklijke Philips NV

第七章市场机会与未来趋势

简介目录
Product Code: 92010

The Hypoxia Treatment Market is expected to grow at a registered CAGR of 3.5% during the forecast period.

Coronavirus disease-2019 (COVID-19) produces severe hypoxemia, exacerbating the COVID-19 damage. Furthermore, the precise impact of hypoxia on COVID-19 patients is uncertain. Early on in the COVID-19 infection, some COVID-19 patients develop a condition known as "silent hypoxia," and it has been observed that hypoxia may aggravate the infection and exacerbate lung cell destruction. According to the study titled "Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? A retrospective cohort study" published in the Lung India in June 2022, around 32% to 65% of COVID-19 patients developed silent hypoxia. Additionally, according to the study titled "Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients" published in the European Review of Medical and Pharmaceutical Science, in May 2020, early-stage oxygen therapy has the potential to treat hypoxia in COVID-19 patients As a result, the market growth is expected to impact by the rise in demand for oxygen therapy among COVID-19 patients.

The market is being driven by both an increase in research and development activity by the pharmaceutical industry and an increase in the prevalence of hypoxia. According to the study titled "The prevalence of hypoxemia among pediatric and adult patients presenting to healthcare facilities in low- and middle-income countries: protocol for a systematic review and meta-analysis" published in the Systematic Review in March 2020, the prevalence of hypoxemia in children under the age of 12 ranged from 2-23% in the low and middle incomes countries. Therefore, the increasing prevalence of hypoxia is anticipated to increase the demand for therapeutic options in the management of diseases, driving up the market's growth.

Additionally, rising R&D activity is anticipated to support market expansion over the forecast period. According to the study titled "Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study " published in the Critical Care in February 2021, an efficient interface for administering noninvasive continuous positive airway pressure (CPAP) is a helmet. Patients might profit from helmet CPAP as a life-saving treatment to increase survival. Moreover, growing research and development spending is expected to boost the market growth. As per the September 2020 update by the Pharmaceutical Research and Manufacturers of America (PhRMA), the PhRMA members had invested nearly USD 83 billion in R&D activities in 2020. Furthermore, as per the same source, more than 260 vaccines are in the pipeline by biopharmaceutical companies for various diseases, including COVID-19, as per PhRMA, 2020.

Thus, all aforementioned factors such as the rising prevalence of hypoxia and growing research and development activity expected to boost the market growth. However, stringent government regulation coupled with the availability of substitute products may restrain the market growth over the forecast period.

Key Market Trends

Asthma are Expected to Witness Healthy Growth Over the Forecast Period

Asthma is one of the most widespread illnesses in the world and a potentially fatal condition that impairs patients' ability to breathe normally. It is a chronic condition that tightens and stretches the lungs' airways, leading to recurrent episodes of shortness of breath, bronchospasm, and reversible airflow obstruction. In addition, there has been a significant increase in cigarette use, which aggravates asthma symptoms. Additionally, as industrialization has grown, so has the number of asthma cases, which could increase the demand for asthma medications in the future. The segment growth is anticipated to be boosted by the rising number of asthma cases. The substantial increase in prevalence and incidence of asthma has led to an increase in the patient population, which has, in turn, increased the demand for these drugs. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), affecting both children and adults. Globally, it affected an estimated 262 million people in 2020 and caused 461,000 deaths.

Furthermore, increasing research and development activity and product launches by the market players are likely to boost the growth of the market. For instance, in March 2021, GlaxoSmithKline PC, in collaboration with IQVIA Pty Ltd, initiated a Phase III clinical trial to evaluate the efficacy and safety of GSK3511294 (Depemokimab) in adult and adolescent patients with severe uncontrolled asthma. The trial is expected to be completed in October 2023. Similarly, in February 2021, AstraZeneca PLC, in collaboration with Amgen Inc., initiated a Phase I clinical trial to evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma. The trial is expected to be completed in September 2021. Thus, the aforementioned factors are expected to drive segment growth over the forecast period.

Thus, all aforementioned factors such as the rising prevalence of hypoxia in asthmatic patients expected to boost the market growth over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America dominates the global market for hypoxia because of the prevalence of hypoxia, rising research and development spending, and rising personal disposable income. hypoxia is majorly associated with respiratory diseases such as asthma, COPD, and Pneumonia and thus the rising incidence of conditions like COPD and asthma contributes to the market's expansion. For instance, according to the National, Heart, Lung, and Blood Institutes updates in March 2022, more than 15 million persons in the United States suffer from COPD each year. The fourth-leading cause of death in the United States was COPD, which is a significant cause of impairment.

Moreover, as per Asthma Canada Annual Report 2021, every day, an estimated 317 Canadians are diagnosed with asthma. Every year, asthma attacks cause over 70,000 hospitalizations. Asthma is the third most common chronic disease in Canada, affecting more than 3.8 million Canadians each year. The high number of patients affected by asthma and COPD increases the demand for drugs for the treatment of the target disease, thereby boosting the growth of this region.

Moreover, growing research and development activity by various institutes likely to propel the growth of the market is expected to witness high growth. For instance, in August 2022, Pgharmazz Inc (United States) received clearance for investigational drug application from the Central Drug Control Organization to conduct phase II clinical trials for Sovateltide in the condition of hypoxic ischemia. Additionally, in January 2022, OxiWear, the first non-intrusive wearable for medical-grade, continuous oxygen monitoring, raised USD 1.25 million in funding.

Thus, all above-mentioned factors are expected to boost the market over the forecast period.

Competitive Landscape

The market studied is a consolidated market owing to the presence of few major market players. With the rising technological advancements and product innovations, mid-size and small-scale companies are increasing their market presence by introducing new devices into the market at competitive prices. Some of the market players are Thermo Fisher Scientific Inc., Resmed, Hamilton Medical, Merck KGaA, Spotlight Labs, LLC., HypOxygen, PharmaShots, Hancock Medical Inc. etc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Hypoxia
    • 4.2.2 Increasing Research and Development Activity
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulation Coupled with Availability of Substitute Product
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Hypoxic Hypoxia
    • 5.1.2 Anaemic Hypoxia
    • 5.1.3 Stagnant Hypoxia
    • 5.1.4 Histotoxic Hypoxia
  • 5.2 By Diseases Type
    • 5.2.1 Chronic Obstructive Pulmonary Disease (COPD)
    • 5.2.2 Pneumonia
    • 5.2.3 Asthma
    • 5.2.4 Others
  • 5.3 By End User
    • 5.3.1 Hospitals/Clinics
    • 5.3.2 Others
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.2 Europe
    • 5.4.3 Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.5 South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific Inc.
    • 6.1.2 Resmed
    • 6.1.3 Merck KGaA
    • 6.1.4 Spotlight Labs, LLC.
    • 6.1.5 HypOxygen
    • 6.1.6 Hancock Medical Inc.
    • 6.1.7 Fisher & Paykel Healthcare Limited
    • 6.1.8 Invacare Corporation
    • 6.1.9 Natus Medical Incorporated
    • 6.1.10 Getinge AB
    • 6.1.11 Hamilton Company
    • 6.1.12 Koninklijke Philips NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS